| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 450 | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 321 | 2014 |
| JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017 | 124 | 2017 |
| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3: 1416–1429. doi: 10.1158/2159-8290 T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... CD-13-0350.[Abstract][CrossRef][Google Scholar], 0 | 56 | |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 54 | 2017 |
| Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess H Peltoketo, L Strauss, R Karjalainen, M Zhang, GW Stamp, DL Segaloff, ... Endocrinology 151 (4), 1872-1883, 2010 | 50 | 2010 |
| Identification of the genes regulated by Wnt-4, a critical signal for commitment of the ovary F Naillat, W Yan, R Karjalainen, A Liakhovitskaia, A Samoylenko, Q Xu, ... Experimental cell research 332 (2), 163-178, 2015 | 47 | 2015 |
| Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing MM Majumder, R Silvennoinen, P Anttila, D Tamborero, S Eldfors, ... Oncotarget 8 (34), 56338, 2017 | 44 | 2017 |
| Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML R Karjalainen, M Liu, A Kumar, L He, D Malani, A Parsons, M Kontro, ... Leukemia 33 (10), 2548-2553, 2019 | 35 | 2019 |
| Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia LL Elo, R Karjalainen, T Öhman, P Hintsanen, TA Nyman, CA Heckman, ... Proteomics 14 (21-22), 2443-2453, 2014 | 14 | 2014 |
| High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options … CA Heckman, M Kontro, T Pemovska, S Eldfors, H Edgren, E Kulesskiy, ... Blood, The Journal of the American Society of Hematology 120 (21), 288-288, 2012 | 3 | 2012 |
| Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2 MM Majumder, M Kontro, H Edgren, D Nicorici, A Parsons, R Karjalainen, ... Cancer Research 72 (8_Supplement), 3175-3175, 2012 | 3 | 2012 |
| Combined targeting of BET family proteins and BCL2 Is synergistic in acute myeloid leukemia cells overexpressing S100A8 and S100A9 R Karjalainen, M Liu, A Kumar, A Parsons, L He, DR Malani, M Kontro, ... Blood 132, 2634, 2018 | 2 | 2018 |
| Identification and clinical exploration of individualized targeted therapeutic approaches in acute myeloid leukemia patients by integrating drug response and deep molecular … D Malani, A Kumar, B Yadav, M Kontro, S Potdar, S Eldfors, J Saarela, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 854-854, 2017 | 2 | 2017 |
| Female mice expressing constitutively active FSH receptor present with a phenotype of premature follicle depletion, premature aging and teratomas H Peltoketo, L Strauss, R Karjalainen, M Zhang, G Stamp, D Segaloff, ... Endocrine Abstracts 21, 2010 | 2 | 2010 |
| September 2013. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... | 2 | 1 |
| Converging molecular evolution in acute myeloid leukaemia C Engen, M Hellesøy, TH Dowling, S Eldfors, B Ferrell, SE Gullaksen, ... medRxiv, 2020.11. 03.20222885, 2020 | 1 | 2020 |
| Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia R Karjalainen, M Popa, M Liu, M Kontro, MM Safont, A Parsons, K Porkka, ... Blood 128 (22), 32, 2016 | 1 | 2016 |
| Identification of precision treatment strategies for high risk multiple myeloma by ex vivo drug sensitivity testing MM Majumder, R Silvennoinen, P Anttila, D Tamborero, S Eldfors, ... Clinical Lymphoma, Myeloma and Leukemia 15, e286, 2015 | 1 | 2015 |
| Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies R Karjalainen, T Pemovska, B Yadav, MM Majumder, M Kontro, K Porkka, ... Blood 122 (21), 1668, 2013 | 1 | 2013 |
